FiscalNote (NYSE:NOTE – Get Free Report) and Predictive Oncology (NASDAQ:POAI – Get Free Report) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.
Profitability
This table compares FiscalNote and Predictive Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FiscalNote | -68.39% | -80.70% | -23.93% |
| Predictive Oncology | -5,065.23% | -732.73% | -235.55% |
Risk and Volatility
FiscalNote has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FiscalNote | $95.41 million | 0.02 | -$65.25 million | ($6.53) | -0.01 |
| Predictive Oncology | $1.66 million | 16.39 | -$12.66 million | ($13.50) | -0.60 |
Predictive Oncology has lower revenue, but higher earnings than FiscalNote. Predictive Oncology is trading at a lower price-to-earnings ratio than FiscalNote, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
54.3% of FiscalNote shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 27.7% of FiscalNote shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for FiscalNote and Predictive Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FiscalNote | 1 | 0 | 1 | 0 | 2.00 |
| Predictive Oncology | 1 | 0 | 0 | 0 | 1.00 |
FiscalNote presently has a consensus target price of $9.75, indicating a potential upside of 13,111.38%. Given FiscalNote’s stronger consensus rating and higher possible upside, research analysts clearly believe FiscalNote is more favorable than Predictive Oncology.
Summary
FiscalNote beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.
About FiscalNote
FiscalNote Holdings, Inc. operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. The company also delivers that intelligence through its suite of public policy and issues management products, as well as powerful tools to manage workflows, advocacy campaigns, and constituent relationships. It serves a customer base that includes businesses comprising the Fortune 100 companies, government agencies, law firms, professional services organizations, trade groups, and non-profits. FiscalNote Holdings, Inc. is headquartered in Washington, District Of Columbia.
About Predictive Oncology
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.
Receive News & Ratings for FiscalNote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FiscalNote and related companies with MarketBeat.com's FREE daily email newsletter.
